Nebenwirkungen · RoActemra
RoActemra 20 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 19
HOS-120292 · Präparat HOS-095117
Infusion-related reactions Infusion-related reactions are defined as all events occurring during or within 24 hours of an infusion. In the 12 week controlled phase, 4 % of patients from the tocilizumab group experienced events occurring during infusion. One event (angioedema) was considered serious and life-threatening, and the patient was discontinued from trial treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T16:00:00Z · SHA-256 258d193083a3b6e0f9782afb87035df8942fd3b113f118da023f638cb2c019c8 · Passage b9624dfaac411f223338f222b44f520f9957a0c1128bc73ddc7f70e02dbe2ca4 · Zeichen 22833–23209 im Abschnitt